Merck reported strong third-quarter results with significant revenue and earnings growth driven by successful product launches like GARDASIL and JANUVIA. The raised full-year EPS guidance and positive management outlook further bolster investor confidence. These factors are likely to drive the stock price higher in the short term.

[2]